State Street’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,650,689
| Closed | -$124M | – | 4998 |
|
|
2022
Q2 | $124M | Sell |
1,650,689
-1,469,237
| -47% | -$65.3M | 0.01% | 1019 |
|
|
2022
Q1 | $83.8M | Buy |
3,119,926
+845,408
| +37% | +$28.4M | ﹤0.01% | 1417 |
|
|
2021
Q4 | $108M | Buy |
2,274,518
+706,465
| +45% | +$31.6M | 0.01% | 1244 |
|
|
2021
Q3 | $104M | Buy |
1,568,053
+112,220
| +8% | +$7.99M | 0.01% | 1225 |
|
|
2021
Q2 | $114M | Buy |
1,455,833
+306,270
| +27% | +$22.6M | 0.01% | 1198 |
|
|
2021
Q1 | $109M | Sell |
1,149,563
-109,157
| -9% | -$13M | 0.01% | 1179 |
|
|
2020
Q4 | $153M | Sell |
1,258,720
-17,784
| -1% | -$1.95M | 0.01% | 870 |
|
|
2020
Q3 | $112M | Buy |
1,276,504
+130,148
| +11% | +$9.07M | 0.01% | 908 |
|
|
2020
Q2 | $74M | Buy |
1,146,356
+77,642
| +7% | +$4.48M | 0.01% | 1167 |
|
|
2020
Q1 | $47.7M | Buy |
1,068,714
+36,063
| +3% | +$1.92M | ﹤0.01% | 1280 |
|
|
2019
Q4 | $64.3M | Buy |
1,032,651
+657,921
| +176% | +$31.3M | ﹤0.01% | 1349 |
|
|
2019
Q3 | $14.1M | Buy |
374,730
+276,483
| +281% | +$12M | ﹤0.01% | 2292 |
|
|
2019
Q2 | $4M | Buy |
+98,247
| New | +$3.5M | ﹤0.01% | 2946 |
|
State Street's TPTX Position: Q3 2022 in Review
State Street sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,650,689 shares — an estimated $124M sold.
State Street first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $153M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- State Street reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- State Street sold 1,650,689 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $124M.
- State Street first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- State Street's Turning Point Therapeutics, Inc. Common Stock position peaked at $153M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on State Street's 13F filing for Q3 2022, filed 15 Nov 2022.